Evaluation of Chromosomal Instability in Diabetic Rats Treated with Naringin

Table 3

Frequency of spermatocyte chromosomal aberrations in testes of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).

Treatment groups (mg/kg)	Different structural chromosomal aberrations screened					Total chromosomal aberrations (%)
	X-Y univalents	Autosomal univalents	F/B	Polyploidy	MV
Nondiabetic control	7	4	2	0	1	2.8 ± 0.44
Nondiabetic + naringin (25)	6	3	1	—	1	2.4 ± 0.89
Nondiabetic + naringin (50)	5	6	1	0	1	2.6 ± 0.89
Diabetes	22	18	3	2	3	9.60 ± 1.51*
Diabetes + naringin (25)	13	10	2	1	1	5.40 ± 1.81^a
Diabetes + naringin (50)	6	5	2	2	1	3.20 ± 1.09^b

^∗𝑃<0.05, versus nondiabetic control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). ^a𝑃<0.05 and ^b𝑃<0.01 versus diabetes alone (Mann-Whitney U test). F: fragments; B: breaks; MV: multivalents having a chain of four chromosomes.